Hepatitis B in the United States: A major health disparity affecting many foreign‐born populations
John W. Ward, Kathy K. Byrd – 24 April 2012
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
George N. Ioannou, Christopher L. Bryson, Noel S. Weiss, Richard Miller, John D. Scott, Edward J. Boyko – 24 April 2012 – Cirrhosis is a leading cause of death among patients infected with human immunodeficiency virus (HIV). We sought to determine risk factors for and time trends in the prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (HCC) among patients diagnosed with HIV who received care in the Veterans Affairs (VA) health care system nationally between 1996 and 2009 (n = 24,040 in 2009).
Role of regulatory T cells in the promotion of transplant tolerance
Itay Shalev, Nazia Selzner, Wendy Shyu, David Grant, Gary Levy – 21 April 2012 – Liver transplantation is now recognized as the most effective therapy for patients with end‐stage acute and chronic liver failure. Despite outstanding short‐term graft and patient survival, liver transplantation continues to face several major challenges, including poor long‐term graft survival due to chronic rejection and major side effects of long‐term immunosuppressive therapy (which is required for the prevention of rejection).
Transient elastography and prognosis of cirrhosis
Annalisa Berzigotti – 19 April 2012
Transcription factor EB: A central regulator of both the autophagosome and lysosome
Enpeng Zhao, Mark J. Czaja – 19 April 2012
Dismantling the myth of “autoanticoagulation” in cirrhosis: An old dogma dies hard
Stephen Caldwell, Nicolas Intagliata – 19 April 2012
Clinical utility of interleukin‐28B testing in patients with genotype 1
Michelle Lai, Nezam H. Afdhal – 18 April 2012
Living donation for the very ill patient with type I hepatorenal syndrome: Are we ready?
Lewis Teperman – 18 April 2012
Small‐for‐size syndrome after living donor liver transplantation: Successful treatment with a transjugular intrahepatic portosystemic shunt
Li Xiao, Fuqiang Li, Bo Wei, Bo Li, Cheng Wei Tang – 18 April 2012 – Small‐for‐size syndrome (SFSS) is a serious complication after living donor liver transplantation (LDLT) that can disrupt liver regeneration and result in hepatic dysfunction. Until now, the treatment options for SFSS after LDLT have been very limited. Here we describe a patient with SFSS after LDLT who was successfully treated with a transjugular intrahepatic portosystemic shunt (TIPS).